Clinical Trial Update: Effects of ODM-109 on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating ODM-109's effects on respiratory function in amyotrophic lateral sclerosis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Amyotrophic Lateral Sclerosis

Drugs mentioned

• ODM-109

Snippet

Sponsor: Orion Corporation, Orion Pharma | Conditions: Amyotrophic Lateral Sclerosis | Phase 2 | Status: COMPLETED